Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

Drug Drug Interaction Clinical Trial

Official title:

Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04840862
• Other study ID #: HS-21-00315
• Status: Recruiting
• Phase: Phase 4
• Start date: May 9, 2022
• Est. completion date: May 2024

Study information

• Verified date: February 2024
• Source: University of Southern California
• Contact: Paul M. Beringer, PharmD
• Phone: 323-442-1402
• Email: beringer[@]usc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.

Description:

Trikafta (Elexacaftor [ELX], Tezacaftor [TEZ], Ivacaftor[IVA]) is contraindicated with concomitant use of strong inducers as co-administration of rifampin decreased the area-under-the concentration time curve (AUC) of IVA by 89%, creating a therapeutic challenge to the treatment of non-tuberculosis mycobacteria (NTM) infection in people with cystic fibrosis (CF). While rifabutin also induces CYP3A4 activity, its effects appear to be more moderate when compared with rifampin. Therefore, we hypothesize that rifabutin can be co-administered with an adjusted dose of ELX/TEZ/IVA in patients being treated for NTM pulmonary disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: May 2024
• Est. primary completion date: May 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Able and willing to sign informed consent prior to any study-related activities.

• Male or female participants between 18 and 65 years of age inclusive.

• Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination findings, and clinical laboratory test results

• Body mass index (BMI) of 17.5 to 30.5 kg/m2, inclusive; and a total body weight >50kg (110 lbs).

• Willing to stop using any herbal or natural health products for 2 weeks prior to and during the study including: Grapefruit, grapefruit juice, St. John's Wort.

• Participant must use a reliable method of birth control while they are participating in the study; for instance an intrauterine device (IUD), condom with spermicidal gel or foam, diaphragm with spermicidal gel or foam, vasectomy, tubal ligation, hysterectomy or abstinence or female must be post-menopausal for at least one year.

Exclusion Criteria:

• Female subjects of childbearing potential with positive urine pregnancy test at screening.

• Female subjects who are breastfeeding.

• Use of CYP3A modulators (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin, azole drugs, telithromycin, clarithromycin, erythromycin)

• Any significant acute or chronic medical illness that might confound the results of the study or pose an additional risk in administrating study drugs to the subject, as determined by the investigator.

• Any condition that could affect drug absorption (eg, gastrectomy, pancreatitis).

• Any major surgery within 4 weeks of study drug administration.

• Blood donation of approximately 1 pint (500 mL) within 56 days before study drug administration.

• Known hypersensitivity to rifamycins

• Patients with hepatic impairment (Child-Pugh Class B or C) and/or with history of hepatobiliary disease or liver function test elevations.

• Renal insufficiency (eGFR < 60 mL/min)

• History of uveitis and/or current eye or vision problems with the exception of corrective lenses.

• Contact lens use during study drug administration.

Related Conditions & MeSH terms

• Drug Drug Interaction

Intervention

Drug:
• Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]
Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
• Rifabutin 300mg
After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.

Locations

Country	Name	City	State
United States	University of Southern California	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
University of Southern California

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	24h area-under the plasma concentration time curve (AUC) of ELX/TEZ/IVA in the absence and the presence of concomitant rifabutin	To assess the impact of rifabutin on the AUC of ELX/TEZ/IVA	22 days
Secondary	Maximum plasma concentration (Cmax) of ELX/TEZ/IVA in the absence and the presence of concomitant rifabutin	To assess the impact of rifabutin on the Cmax of ELX/TEZ/IVA	22 days